Health Affairs, 25, no. 5 (2006): 1340-1346 doi: 10.1377/hlthaff.25.5.1340 © 2006 by Project HOPE	New Online   Senate Health Reform Bill   Rewarding Providers   Public Option Policy Brief   Health Reform & Abortion   Delivery System Reform

This Article Full Text (HTML) Reprint (PDF) Submit a response to this article Alert me when this article is cited Alert me when Comments are posted Alert me if a correction is posted Services E-mail this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Archive Download to Citation Manager Reprints & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (1) Citing Articles via Google Scholar Google Scholar Articles by Monroe, C. D. Articles by Wagner, R. Search for Related Content PubMed PubMed Citation Articles by Monroe, C. D. Articles by Wagner, R. Related Collections Access To Care Insurance Coverage Managed Care Managed Care - Consumers Business Of Health Pharmaceuticals Chronic Care Quality Of Care Research And Technology Health Spending Consumer Issues Insurance Market

Specialty Drugs

PERSPECTIVE

Kaiser Permanente’s Evaluation And Management Of Biotech Drugs: Assessing, Measuring, And Affecting Use

Two decades into the age of high-cost biotechnology medications, health care organizations are challenged to provide safe, effective treatment while managing costs. In a market lacking generic biotech drugs, health care organizations have few opportunities to negotiate reduced pricing; other strategies must be devised to manage use. Kaiser Permanente leverages its integrated health care delivery system to deploy management tools for costly therapies: evidence analysis, usage measurements, and multidisciplinary planning. Evidence-based medicine and realization of value provided by new therapies will depend on data capture and outcomes measurement, tools that are crucial to Kaiser Permanente’s management of biotechnologies and effective use of members’ financial resources.

                      What's this?

This article has been cited by other articles:

				L. F. Hogle Pragmatic Objectivity and the Standardization of Engineered Tissues Social Studies of Science, October 1, 2009; 39(5): 717 - 742. [Abstract] [PDF]